In a febrile child fulfilling the diagnostic criteria for Kawasaki disease who now has jaundice and diarrhea, what is the underlying cause of these findings?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Jaundice and Diarrhea in Kawasaki Disease

Jaundice and diarrhea in this febrile child with Kawasaki disease are direct manifestations of the systemic vasculitis affecting the gastrointestinal system and liver, representing recognized non-cardiac complications of the acute inflammatory process.

Underlying Pathophysiology

The gastrointestinal and hepatic findings in Kawasaki disease result from the widespread systemic vasculitis that characterizes this condition. While coronary arteries are the most clinically significant target, the inflammatory process affects multiple organ systems simultaneously during the acute phase 1.

Gastrointestinal Manifestations

Diarrhea is a common gastrointestinal manifestation occurring in approximately one-third of patients with Kawasaki disease 1. The American Heart Association guidelines explicitly list diarrhea among the recognized gastrointestinal findings, along with vomiting and abdominal pain 1. These symptoms result from:

  • Intestinal inflammation and edema secondary to vasculitis affecting the mesenteric vessels 2
  • Bowel wall involvement that can progress to more severe complications like intestinal pseudo-obstruction, though this is less common 1, 3
  • The systemic inflammatory state causing altered intestinal motility and function 2

Hepatobiliary Manifestations

Jaundice in Kawasaki disease reflects hepatic involvement with hepatitis and cholestasis 1. The American Heart Association guidelines specifically recognize both "mild jaundice" and "mild increase of serum transaminase levels" as documented gastrointestinal findings 1. The mechanisms include:

  • Hepatitis from direct vasculitic inflammation of hepatic vessels, causing hepatocellular injury and elevated transaminases 1
  • Cholestatic jaundice that can present as acute febrile cholestatic jaundice in some cases 4
  • Gallbladder hydrops (acute acalculous distention), which occurs in approximately 15% of patients during the first 2 weeks and can contribute to biliary obstruction 1

Clinical Context and Recognition

These findings are part of the broader spectrum of "other significant clinical and laboratory findings" that support the diagnosis but are not part of the principal diagnostic criteria 1. The presence of gastrointestinal symptoms can actually complicate diagnosis:

  • Prominent gastrointestinal symptoms may lead to surgical admission with other Kawasaki features being overlooked, representing a common diagnostic pitfall 5
  • Some children may even present as an acute surgical abdomen, though this is rare 1
  • Hepatic enlargement frequently accompanies the jaundice 1

Important Clinical Caveats

The gastrointestinal and hepatic manifestations typically resolve with appropriate treatment of the underlying Kawasaki disease 2. Key points include:

  • These findings reflect the acute inflammatory phase and should improve with IVIG and aspirin therapy 2
  • The presence of jaundice and diarrhea does not change the fundamental treatment approach, which remains high-dose IVIG and aspirin 1
  • Persistent or worsening gastrointestinal symptoms after IVIG may indicate treatment resistance and warrant consideration of second-line therapies 6
  • Hypoalbuminemia commonly accompanies the gastrointestinal involvement and contributes to the clinical picture 2

Do not mistake these gastrointestinal symptoms for a separate infectious or surgical condition—they are integral manifestations of the systemic vasculitis in Kawasaki disease 1, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Multisystem Imaging Manifestations of Kawasaki Disease.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2022

Research

Two cases of Kawasaki disease presented with acute febrile jaundice.

The Turkish journal of pediatrics, 2017

Guideline

Differential Diagnoses for Kawasaki Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Kawasaki disease: an evolving paradigm.

Autoimmunity reviews, 2015

Related Questions

What is the treatment for a young child under 5 years old diagnosed with Kawasaki disease?
Is there a benefit to using anti-radiation (anti-rad) glasses in pediatric patients, especially those under 5 years old, undergoing diagnostic imaging for Kawasaki disease?
What is Kawasaki disease?
What are the causes of strawberry tongue?
What's the next evaluation step for a 4-year-old with fever, runny nose, cough, bilateral conjunctivitis, dry oral mucosa, maculopapular rash, edema and erythema of palms and soles, and a nontender enlarged cervical lymph node?
What is the best overall treatment approach for Bipolar I disorder?
What is the complete evaluation for non‑alcoholic fatty liver disease in an adult patient?
What is the appropriate emergency department management for a stable adult presenting with acute unexplained shortness of breath?
In hereditary transthyretin amyloidosis polyneuropathy, should disease-modifying therapy be given to all patients or only to those with painful neuropathy?
Can Parkinson's disease medications, such as levodopa/carbidopa, dopamine agonists (pramipexole, ropinirole, rotigotine), MAO‑B inhibitors (monoamine oxidase B inhibitors) (selegiline, rasagiline), COMT inhibitors (catechol‑O‑methyltransferase inhibitors) (entacapone, tolcapone), amantadine, or anticholinergics, cause diarrhea in older adults?
In a 38‑year‑old white male with normal glycemic control, normal thyroid function, normal blood pressure, non‑smoker, and low‑density lipoprotein cholesterol (LDL‑C) 206 mg/dL, should I calculate his 10‑year atherosclerotic cardiovascular disease (ASCVD) risk and start high‑intensity statin therapy even if the risk score is below 10%?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.